AstraZeneca's Breztri Shows Positive Results in Phase III Asthma Trials
AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.
AstraZeneca PLC (NASDAQ:AZN) announced on February 13 the full results from the positive Phase III KALOS and LOGOS trials, showing that the company's Breztri Aerosphere exhibited statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines: Symbicort, PT009, and the Symbicort and PT009 treatment groups combined. Breztri is a single-inhaler, fixed-dose triple-combination of ICS/LABA and a long-acting muscarinic antagonist.
AstraZeneca further reported that Breztri also showed clinically meaningful reductions in the annualised rate of severe asthma exacerbations versus ICS/LABA medicines in patients with or without a recent asthma exacerbation in the pooled analysis of KALOS and LOGOS. There were no new safety or tolerability signals identified for Breztri in KALOS or LOGOS.
In a separate development, AstraZeneca received an update from Deutsche Bank on February 16, with the firm reiterating a Sell rating on the stock and setting a price target of £115.
AstraZeneca PLC is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca distributes its products and services through local representative offices and distributors.